CJC-1295 Dosage Guide
GH/IGF-1 pharmacokinetic data and research protocols from the landmark Teichman et al. Phase I study. Presented as "dose used in Study X" — not a personal recommendation.
Research reference only. CJC-1295 is not FDA-approved for human use. This guide summarises peer-reviewed scientific literature. Not medical advice. See our full disclaimer.
At a Glance
Source: Teichman SL et al., J Clin Endocrinol Metab, 2006. PMID 16352683
Phase I Human Study Data
Key finding: Dose-dependent GH elevation was observed across all dose levels. CJC-1295 produced sustained increases in mean plasma GH concentrations, with a prolonged half-life compared to native GHRH(1-29) due to its engineered amino acid substitutions.
View on PubMed →CJC-1295 vs CJC-1295 with DAC
Two distinct variants are used in research. Understanding the difference is important for protocol design:
| Property | CJC-1295 (no DAC) | CJC-1295 with DAC |
|---|---|---|
| Also called | Modified GRF 1-29 / Mod-GRF | CJC-1295 DAC |
| Half-life | ~30 minutes | 6–8 days |
| GH release pattern | Pulsatile | Sustained / continuous |
| Dosing frequency | Multiple times daily | Once weekly or less |
| Albumin binding | No | Yes (via DAC linker) |
The Phase I Teichman study used CJC-1295 without DAC. The Teichman 2006 paper also investigated the DAC variant in a separate cohort; the DAC arms demonstrated markedly extended half-lives consistent with albumin binding kinetics.
Mechanism of Action
CJC-1295 is a synthetic analogue of GHRH(1-29) — growth hormone-releasing hormone — the endogenous hypothalamic peptide that drives pituitary GH secretion. It was engineered with four amino acid substitutions to improve metabolic stability and half-life relative to native GHRH.
CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotrophs, activating adenylyl cyclase and PKA signaling cascades that drive GH synthesis and secretion. It acts synergistically with ghrelin receptor agonists (e.g. Ipamorelin) because the two stimulate GH via complementary receptor pathways.
Reconstitution for Research Use
Add 1 mL bacteriostatic water → concentration 2,000 mcg/mL (2 mg vial)
Add 2 mL bacteriostatic water → concentration 1,000 mcg/mL (2 mg vial)
Store reconstituted peptide at 2–8°C. Use within 4–8 weeks. Protect from light. Do not freeze after reconstitution.
Frequently Asked Questions
What dose of CJC-1295 was used in the Phase I clinical study?
Teichman SL et al. (J Clin Endocrinol Metab, 2006; PMID 16352683) tested single SC doses of 30, 60, 120, and 180 mcg/kg in healthy adults. Dose-dependent GH elevation was observed across all dose levels. This is the primary Phase I reference for CJC-1295 dosing data.
What is the difference between CJC-1295 and CJC-1295 with DAC?
CJC-1295 (no DAC) has a half-life of ~30 minutes and produces pulsatile GH release. CJC-1295 with DAC incorporates a Drug Affinity Complex linker that binds to serum albumin, extending the half-life to 6–8 days and producing sustained GH elevation. Research protocols select between them based on whether pulsatile or sustained GH stimulation is the study objective.
Why is CJC-1295 often stacked with Ipamorelin?
CJC-1295 (a GHRH receptor agonist) and Ipamorelin (a GHSR-1a agonist) act on different receptors in the GH secretory cascade. CJC-1295 sensitizes somatotrophs via GHRHR signaling; Ipamorelin provides the GHSR pulsatile stimulus. Research has shown synergistic GH secretion when both pathways are activated together, making this a commonly studied combination.
How does CJC-1295 work as a GHRH analogue?
CJC-1295 is a synthetic analogue of GHRH(1-29) engineered with four amino acid substitutions for improved stability. It binds GHRH receptors on pituitary somatotrophs, activating adenylyl cyclase and PKA cascades that drive GH synthesis and secretion.